Global Biotherapeutics Cell Line Development Market to Reach US$99.8 mn by 2022


Posted July 18, 2016 by MarketTrends

As the biotherapeutics industry continues to grow exponentially, there has been an increase in the demand for mammalian cell line development.

 
The biotherapeutics industry continues to grow swiftly owing to the growing demand for mammalian cell line development. Over the past few years, big pharmaceutical companies have been pursuing the development of small molecule drugs by aggressively investing in biotechnology. The increasing occurrence of various diseases has led to an increase in the demand for biotherapeutics.

The rising aging population is expected to propel the global biotherapeutics cell line development market in the next few years. As per the data presented by the International Diabetes Federation (2014), the percentage of the population suffering from diabetes is expected to increase to 53% during the period from 2014 to 2035.

Avail a Free Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272

The global biotherapeutics cell line development market is segmented on the basis of geography, process, and cell line development option. Based on process, the global biotherapeutics cell line development market is classified into single cell cloning and transfection. The single cell cloning segment is sub-segmented by method into manual limited dilution cloning, ClonePix, FACS, and others. In 2014, the global biotherapeutics cell line development market was led by the manual limited dilution cloning segment, which accounted for 37.4%.

Based on geography, the global biotherapeutics cell line development market is divided into Europe, the Middle East and Africa, Latin America, Asia Pacific, and North America. In 2014, the global biotherapeutics cell line development market was dominated by North America, followed by Europe.

The increasing demand for biotherapeutics cell line development due to the rising aging population is expected to propel the North America biotherapeutics cell line development market in the years to come. In 2014, Asia Pacific was the third largest market in the global biotherapeutics cell line development market. It is expected that the Asia Pacific biotherapeutics cell line development market will grow at the highest CAGR through the forecast period.

Some of the prominent players operating in the global biotherapeutics cell line development market are Becton Dickinson & Company (U.S.), Boehringer Ingelheim Group (Germany), CMC Biologics A/S (Denmark), EMD Millipore (U.S.), ProBioGen AG (Germany), Sony Biotechnology Inc. (U.S.), Beckman Coulter (U.S.), Catalent Inc. (U.S.), Lonza Group Ltd. (Switzerland), and Partec (Sysmex Corporation, Japan). With many new biotherapeutics cell line development methods being introduced by leading players, the global market is expected to be highly competitive in the years to come.

Browse Full Research Report: http://www.transparencymarketresearch.com/biotherapeutics-cell-line-development-market.html

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By MarketTrends
Website Biotherapeutics Cell Line Development Market
Phone +1-518-618-1030
Business Address State Tower, 90 State Street, Suite 700
Albany, NY 12207 United States
Country United States
Categories Health
Tags biotherapeutics cell line development market , global biotherapeutics cell line development market
Last Updated July 18, 2016